Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

ClinicalTrials.gov ID

NCT07379827

Lead Sponsor

Bristol-Myers SquibbINDUSTRY

Overall Status

Recruiting

Study Type

Observational

Enrollment

1,500Estimated

Last Update Posted

Aug 19, 2026Actual

Start Date

Feb 26, 2026Actual

Primary Completion Date

Jun 20, 2028Estimated

Completion Date

Jun 20, 2028Estimated

Official Title

Effectiveness and Adverse-effect Switch Evaluation

Brief Summary

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

• Schizophrenia

• Xanomeline and trospium chloride (KarXT)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Participants (or caregiver/legal guardian) must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICF or signed an electronic ICF in accordance with regulatory, local, and institutional guidelines.

• Adults ≥ 18 years of age at Baseline who are willing and able, in the judgement of the treating clinician, to participate in routine clinical care and follow up.

• Schizophrenia, confirmed by the treating clinician's judgement or physician decision to treat the patient with receiving xanomeline and trospium chloride (KarXT) for schizophrenia made prior to and independently of participation in this study. Current Antipsychotic Treatment: Participant must fall into one of the categories below:

  • Be within <16 weeks of initiating treatment with KarXT with intent to discontinue prior antipsychotic treatment(s) OR
  • On a stable regimen (dose and frequency consistent with the drug label and/or at a stable dose based on the judgement of the Investigator for at least 30 days prior to screening) of treatment with 1 or more antipsychotics with plan to discontinue and switch to treatment with KarXT from a prior antipsychotic treatments(s). NOTE: The decision to switch for reasons of safety, tolerability, and/or efficacy will be made independently by the treating clinician and/or the patient and is not dictated by the study. Participants can be enrolled during tapering/discontinuing process from prior antipsychotic treatment(s). Individuals who are not currently receiving treatment for schizophrenia are not eligible for the study. Any antipsychotic treatments must be recorded as concomitant medications.

• Concomitant psychiatric medications (eg, antidepressants, mood stabilizers, anxiolytics) are permitted and are recommended to remain at a stable dose during the study period.

Exclusion Criteria:

• Prior use of KarXT that has been discontinued for any reason prior to Baseline.
• Participation in an interventional study within the last 30 days or plans to participate in an interventional study at the time of eligibility or baseline through the study period.
• Known hypersensitivity to xanomeline or trospium chloride, or history or high risk of urinary retention, gastric retention, moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment, or narrow-angle glaucoma.
• In the opinion of the treating clinician, unstable psychiatric or medical conditions that would prevent the participant from safely switching to KarXT. Hospitalized individuals who have been switched to KarXT or are switching treatment to KarXT are permitted to be enrolled at discharge if they are < 16 weeks from initiation of KarXT.
• Participants who are pregnant, planning to become pregnant, or breastfeeding.

Observational Model

Cohort

Time Perspective

Other

Lead Sponsor

Bristol-Myers SquibbINDUSTRY

305-805-0921

404-616-4752

• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

  NCT03697252

  CompletedInterventionalPhase 2Updated Oct 26, 2020
• An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

  NCT05643170

  TerminatedInterventionalPhase 3Updated Jun 12, 2024
• Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

  NCT07101094

  RecruitingObservationalUpdated Aug 19, 2026
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413

  CompletedInterventionalPhase 3Updated May 5, 2026
• A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia

  NCT07802132

  Not yet recruitingObservationalUpdated Sep 3, 2026
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

  NCT04659161

  CompletedInterventionalPhase 3Updated Dec 12, 2023